Dr. Jeffrey S. Heier

• 
  www.retinatoday.com/issues/1107/1107_08.php - [Cached Version]
  Published on: 10/8/2008    Last Visited: 1/11/2008  

  Reviewed by Jeffrey S. Heier, MD
  
  Positive results from the full analysis of the primary 12-week endpoint of a phase 2 study evaluating intravitreal antivascular endothelial growth factor (VEGF Trap-Eye; Regeneron Pharmaceuticals, Tarrytown, NY) in neovascular age-related macular degeneration (AMD) were reported in Boston at the Retina Society Annual Scientific Meeting.1
  
  Phase 2 data of VEGF Trap-Eye met the primary study endpoint of a statistically significant reduction in retinal thickness after 12 weeks of treatment compared with baseline (all five dose groups combined, mean decrease of 119 µm, PJeffrey Heier, MD, clinical ophthalmologist at Ophthalmic Consultants of Boston, primary investigator in the phase 2 study, and chair of the steering committee for the phase 3 VEGF Trap: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (VIEW 1) trial, presented the results.Dr. Heier is also a member of the Retina Today editorial board.
  
  The mean change from baseline in visual acuity, a secondary endpoint of the study, also showed statistically significant improvement (all groups combined, increase of 5.7 letters, PJeffrey Heier, MD, is clinical ophthalmologist at Ophthalmic Consultants of Boston and a member of the Retina Today editorial board.He may reached at JSHEIER@eyeboston.com.
  
  Heier JS for the CLEAR-IT 2 Investigators.

• 
  www.osnsupersite.com/view.asp?rID=24848 - [Cached Version]
  Published on: 11/16/2007    Last Visited: 1/21/2008  

  In another presentation, Jeffrey S. Heier, MD, presented the latest software on Heidelberg's Spectralis.The software gives more detailed 3-D photos of the ocular coherence tomography that can be seen in direct connection with fluorescein angiography images.
  
  "We are seeing things now that we weren't able to see 2 years ago or even 6 months ago," he said.
  
  The software offers the same advantages as the new Heidelberg Edge Perimeter: the ability to repeat tests and measure progression, a combination of technologies and a more nuanced detection of change.
  
  "This is clearly the easiest way, but whether it is clinically relevant still remains to be seen," Dr. Heier said.

• 
  www.rehabpub.com/press_release.asp?id=10194198 - [Cached Version]
  Published on: 3/28/2008    Last Visited: 3/30/2008  

  Jeffrey S. Heier, MD, a retinal specialist, partner at Ophthalmic Consultants of Boston and a consultant for NeoVista, presented the one-year data obtained from trial participants (mean age, 72 years) who enrolled from June 2006to April 2007at two centers in Brazil and one in Mexico.
  
  "As more data are collected and analyzed surrounding this one-time surgical procedure, we're continuing to see the potential of the concomitant approach to treat wet AMD," said Dr. Heier

• 
  phx.corporate-ir.net/phoenix.zhtml?c=119576&p=irol-news - [Cached Version]
  Published on: 10/1/2007    Last Visited: 9/25/2008  

  "These results reaffirm the decision to study both the 0.5 mg and 2 mg monthly doses in the Phase 3 program," stated Jeffrey Heier, M.D., a clinical ophthalmologist at Ophthalmic Consultants of Boston, a primary investigator in the Phase 2 study, and chair of the steering committee for the Phase 3 VIEW 1 trial.

• 
  www.osnsupersite.com/view.asp?rID=24718 - [Cached Version]
  Published on: 11/16/2007    Last Visited: 1/21/2008  

  During Retina Subspecialty Day, Dr. Heier showed that ANCHOR results were stable over all sub-groups up to 24 months.
  
  The data support the earlier positive results of the ANCHOR study that favored ranibizumab over photodynamic therapy (PDT) at all key outcomes, Jeffrey S. Heier, MD, said at the Retina Subspecialty Day preceding the annual American Academy of Ophthalmology meeting.
  
  "I've never heard anyone question Lucentis' (ranibizumab, Genentech) efficacy," he said.
  
  Dr. Heier pointed to "dramatic treatment results" in this "remarkably consistent therapy."
  ...
  "Ranibizumab remains a consistent and highly effective treatment," Dr. Heier said.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/w - [Cached Version]
  Published on: 3/28/2008    Last Visited: 3/28/2008  

  Jeffrey S. Heier, MD, a retinal specialist, partner at Ophthalmic
  ...
  concomitant approach to treat wet AMD," said Dr. Heier."Unlike previous

• 
  www.retinatoday.com/issues/0508/0508_12.php - [Cached Version]
  Published on: 10/8/2008    Last Visited: 7/5/2008  

  By Jeffrey S. Heier, MD
  ...
  Jeffrey S. Heier, MD, is a Clinical Ophthalmologist at Ophthalmic Consultants of Boston and a member of the Retina Today editorial board.He states that he receives research support from Allergan, Inc., Heidelberg Engineering, Inc. and Ista; serves on the scientific advisory board for Allergan Inc., Genentech, Heidelberg Engineering, Inc. and Ista; and is a consultant to Heidelberg Engineering, Inc., Dr. Heier can be reached at jsheier@eyeboston.com.
  
  Gass JDM.Stereoscopic Atlas of Macular Disease Diagnosis and Treatment, Vol.2.Mosby: St Louis, 1997. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ.In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics.Invest Ophthalmol Vis Sci.1995;36(3):718,729.

• 
  www.lifesciencesinfo.com/cod/speakers_lower.asp?pid=USC - [Cached Version]
  Published on: 4/5/2004    Last Visited: 11/29/2004  

  Jeff Heier, M.D., Ophthalmic Consultants of Boston; Genentech

• 
  www.corporate-ir.net/ireye/ir_site.zhtml?ticker=OXGN&sc - [Cached Version]
  Published on: 6/20/2005    Last Visited: 8/1/2007  

  Jeffrey S. Heier, M.D. Joins OXiGENE's Clinical Trials Advisory Board
  
  "In another development related to our programs for diseases of the eye, OXiGENE welcomes Jeffrey S. Heier, M.D. to our Clinical Trials Advisory Board," continued Mr. Driscoll.
  ...
  Heier is an outstanding member of the ophthalmology community whose research specializes in several fields, including macular degeneration.He has been at the forefront of clinical development of several of the new agents being tested for wAMD and we believe Dr. Heier will make important contributions to the development plans for our VTAs in ophthalmic indications."With regard to his appointment to OXiGENE's Clinical Trials Advisory Board, Dr. Heier commented, "OXiGENE's vascular targeting approach shows promise in treating debilitating diseases of the eye, including macular degeneration, because it acts by both preventing the proliferation of new blood vessels and regressing the already formed aberrant vasculature.I am pleased to advise OXiGENE in their efforts to develop their VTAs to fight serious ocular diseases for which there continues to be a significant unmet medical need."
  
  Dr. Heier is a Vitreoretinal Specialist at Ophthalmic Consultants of Boston, Co-Director of the Vitreoretinal Fellowship at OCB/Tufts Medical School, and President of the Center for Eye Research and Education in Boston, Massachusetts.Dr. Heier is an Assistant Professor at Tufts University School of Medicine and a Clinical Instructor at Harvard University Medical School.Dr. Heier received a medical degree from Boston University School of Medicine in Massachusetts, and subsequently completed a transitional internship and ophthalmic residency at Fitzsimons Army Medical Center.Dr. Heier completed a vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts University School of Medicine.Dr. Heier's research interests are focused on age-related macular degeneration (ARMD), diabetic retinopathy, and innovation in vitreoretinal surgical instrumentation.Dr. Heier lectures nationally and internationally regarding innovative treatments of devastating eye diseases such as macular degeneration and diabetic retinopathy.

• 
  peerviewpress.docguide.com/guestFaculty.do;jsessionid=C - [Cached Version]
  Published on: 5/21/2004    Last Visited: 2/1/2008  

  Jeffrey S. Heier, MDCenter for Eye Research and Education

Page:  1 2 3 4 5